

AMENDMENTS

The listing of claims will replace all prior versions, and listings, or claims in the application.

In the Claims

Claims 1-27 (cancelled)

Claim 28 (currently amended): A purified analog of a T cell-dependent immunogen implicated in an antibody-mediated pathology, said analog comprising an epitope that binds specifically to an antibody to which the immunogen binds specifically, wherein the analog lacks T cell epitopes capable of activating T cells in an individual having the antibody-mediated pathology, and wherein the analog is a polypeptide.

Claim 29 (previously presented): The analog of claim 28, further comprising a functional group for coupling to a carrier.

Claim 30 (cancelled)

Claim 31 (previously presented): A composition comprising the analog of claim 28 and a buffer.

Claim 32 (previously presented): A complex comprising the analog of claim 28 bound to an antibody to which the immunogen binds specifically.

Claim 33 (withdrawn): A method of identifying a polypeptide analog of a T cell-dependent immunogen comprising the steps of:

- (a) screening a panel or library of candidate polypeptides for the presence of one or more B cell epitope(s) that specifically binds to antibodies to which the immunogen binds specifically;
- (b) screening said candidate polypeptides identified in step (a) for candidate polypeptides lacking T cell epitope(s); and
- (c) selecting a polypeptide analog from said candidate polypeptides that bind to the antibodies of step (a), but that do not contain T cell epitope(s) as determined by step (b).

Claim 34 (withdrawn): A method of making a polypeptide analog of a T cell-dependent immunogen comprising the step of removing T cell epitope(s) from a polypeptide comprising an epitope that binds specifically to antibodies to which the immunogen binds specifically.

Claim 35 (withdrawn): The method of claim 34, wherein the T cell epitope(s) is removed by altering the T cell epitope(s).

Claim 36 (withdrawn): The method of claim 34, wherein the T cell epitope(s) is removed by deleting the T cell epitope(s).

Claim 37 (withdrawn): A method of making a polypeptide analog of a T cell-dependent immunogen comprising the steps of

- (a) synthesizing the polypeptide analog, whereby the polypeptide analog comprises an epitope that binds specifically to antibodies to which the immunogen binds specifically, wherein the analog lacks T cell epitopes capable of activating T cells in an individual; and
- (b) purifying the analog.

Claim 38 (currently amended): A purified analog of a T cell-dependent immunogen implicated in an antibody-mediated pathology, said analog comprising an epitope that binds specifically to an antibody to which the immunogen binds specifically, wherein the analog has a T cell stimulation index below about 2-3 in an individual having the antibody-mediated pathology, and wherein the analog is a polypeptide.

Claim 39 (previously presented): The analog of claim 38, wherein the analog has a T cell stimulation index below about 1-2.

Claim 40 (previously presented): The analog of claim 38, further comprising a functional group for coupling to a carrier.

Claim 41 (cancelled)

Claim 42 (previously presented): A composition comprising the analog of claim 38 and a buffer.

Claim 43 (previously presented): A complex comprising the analog of claim 38 bound to an antibody to which the immunogen binds specifically.